PROGENICS PHARMACEUTICALS IN's ticker is PGNX and the CUSIP is 743187106. A total of 151 filers reported holding PROGENICS PHARMACEUTICALS IN in Q1 2019. The put-call ratio across all filers is 1.60 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2020 | $52,000 | -90.1% | 138,663 | 0.0% | 0.00% | -100.0% |
| Q1 2020 | $527,000 | -25.4% | 138,663 | 0.0% | 0.00% | 0.0% |
| Q4 2019 | $706,000 | +0.7% | 138,663 | 0.0% | 0.00% | 0.0% |
| Q3 2019 | $701,000 | -18.1% | 138,663 | 0.0% | 0.00% | 0.0% |
| Q2 2019 | $856,000 | +33.1% | 138,663 | 0.0% | 0.00% | 0.0% |
| Q1 2019 | $643,000 | +11.1% | 138,663 | +0.7% | 0.00% | 0.0% |
| Q4 2018 | $579,000 | -31.8% | 137,761 | +1.7% | 0.00% | 0.0% |
| Q3 2018 | $849,000 | -21.6% | 135,411 | +0.5% | 0.00% | -33.3% |
| Q2 2018 | $1,083,000 | +8.6% | 134,677 | +0.7% | 0.00% | +50.0% |
| Q1 2018 | $997,000 | +25.4% | 133,678 | 0.0% | 0.00% | 0.0% |
| Q4 2017 | $795,000 | +264.7% | 133,678 | +350.4% | 0.00% | +100.0% |
| Q3 2017 | $218,000 | +9.0% | 29,678 | +0.7% | 0.00% | 0.0% |
| Q2 2017 | $200,000 | -25.7% | 29,478 | +3.5% | 0.00% | 0.0% |
| Q1 2017 | $269,000 | – | 28,478 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadfin Capital, LLC | 17,902,338 | $135,342,000 | 5.88% |
| TIGER MANAGEMENT L.L.C. | 1,288,454 | $9,741,000 | 1.91% |
| Phocas Financial Corp. | 1,047,181 | $7,917,000 | 0.69% |
| TUDOR INVESTMENT CORP ET AL | 2,370,503 | $17,921,000 | 0.62% |
| EAM Investors, LLC | 553,309 | $4,183,000 | 0.58% |
| Baker Brothers Advisors | 4,449,797 | $33,640,000 | 0.34% |
| TFS CAPITAL LLC | 463,740 | $3,506,000 | 0.33% |
| FEDERATED HERMES, INC. | 13,508,290 | $102,123,000 | 0.32% |
| Rotella Capital Management, Inc. | 36,473 | $276,000 | 0.24% |
| OXFORD ASSET MANAGEMENT LLP | 1,103,848 | $8,351,000 | 0.18% |